Our Pricing

How to Switch From Mounjaro To Wegovy: UK Clinical Guide

Many patients considering a switch from Mounjaro to Wegovy want to understand the clinical rationale, dosing equivalents, and cost implications of transitioning between these two GLP-1 receptor agonists. As a UK-registered pharmacy with extensive experience supporting weight loss medication transitions, we've guided hundreds of patients through this process safely and effectively. This guide provides evidence-based protocols for switching from tirzepatide to semaglutide under UK prescriber supervision.

Why Patients Switch From Mounjaro To Wegovy in the UK

The decision to switch from Mounjaro to Wegovy typically stems from cost considerations, supply availability, or individual response profiles. Wegovy (semaglutide) currently offers a more competitive price point in the UK market, starting from £124.99 compared to Mounjaro's £124.99 making it an attractive option for long-term weight management [1]. Both medications belong to the GLP-1 receptor agonist class and share similar mechanisms of action, though tirzepatide additionally activates GIP receptors.

Clinical data from the STEP trials for semaglutide and SURMOUNT trials for tirzepatide demonstrate that both medications achieve substantial weight loss, with average reductions of 15-20% of body weight over 68-72 weeks [2]. Some patients switch from Mounjaro to Wegovy after achieving initial weight loss goals, seeking a maintenance option with lower monthly costs. Others may experience supply chain disruptions or prefer the established track record of semaglutide, which received UK licensing for weight management earlier than tirzepatide.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) notes that the switch from Mounjaro to Wegovy should always be conducted under UK prescriber guidance, as individual factors including current dose, weight loss progress, and tolerability history inform the optimal transition protocol. At Cured Pharmacy, we provide transparent pricing and clinical support throughout the switching process, ensuring continuity of care during medication transitions.

Clinical Protocol for Switching From Mounjaro To Wegovy

The recommended approach when you switch from Mounjaro to Wegovy involves careful dose matching and timing to maintain therapeutic effect while minimising side effects. Unlike direct dose equivalents, the transition requires clinical judgment based on your current tirzepatide dose and individual response. Most UK prescribers recommend completing your current Mounjaro injection cycle before initiating Wegovy, allowing a 5-7 day washout period [3].

For patients on Mounjaro 2.5mg, the typical starting dose of Wegovy is 0.25mg weekly, following the standard titration schedule. Those on higher Mounjaro doses (5mg-15mg) may start Wegovy at 0.5mg or 1mg depending on tolerability history and prescriber assessment. The key principle is avoiding abrupt transitions that could trigger gastrointestinal side effects or compromise glycaemic control in patients with type 2 diabetes.

Dose Titration Timeline When Switching From Mounjaro To Wegovy

The standard Wegovy titration schedule spans 16-20 weeks, gradually increasing from 0.25mg to the maintenance dose of 2.4mg weekly [4]. This measured approach allows your digestive system to adapt to semaglutide's effects on gastric emptying and appetite regulation. Patients switching from Mounjaro often tolerate faster titration due to prior GLP-1 exposure, but this must be determined by your UK prescriber based on individual factors.

During the switch from Mounjaro to Wegovy, monitoring weight trends, side effect profiles, and satiety levels helps optimise the transition. Most patients maintain their weight loss trajectory when switching, with some experiencing enhanced tolerability on semaglutide due to its single-receptor mechanism. Our clinical team at Cured Pharmacy coordinates with prescribers to ensure seamless medication transitions and ongoing support throughout the titration period.

Cost Comparison: Switch From Mounjaro To Wegovy UK Pricing

Financial considerations often drive the decision to switch from Mounjaro to Wegovy, particularly for patients funding treatment privately. Wegovy pricing at Cured Pharmacy starts from £124.99 per month, representing a £124.99 monthly saving compared to Mounjaro's £124.99 starting price. Over a 12-month treatment course, this translates to potential savings exceeding £124.99 making Wegovy a more sustainable option for long-term weight management.

The cost differential becomes even more significant at maintenance doses. Wegovy 2.4mg pens remain competitively priced throughout the treatment journey, whereas Mounjaro's higher maintenance doses (10mg-15mg) command premium pricing. New patients switching from Mounjaro to Wegovy at Cured Pharmacy can access an additional £20 discount on their first order using code Weightlossnew, further reducing initial transition costs.

It's worth noting that both medications require ongoing prescription and clinical monitoring, with consultation fees included in our transparent pricing structure. Unlike some UK pharmacies that advertise low medication costs but add hidden consultation charges, Cured Pharmacy provides upfront total pricing, ensuring you can accurately compare costs when planning your switch from Mounjaro to Wegovy.

Expected Outcomes When You Switch From Mounjaro To Wegovy

Clinical evidence suggests that patients who switch from Mounjaro to Wegovy can maintain their weight loss achievements when the transition is managed appropriately. The STEP 1 trial demonstrated that semaglutide 2.4mg produces average weight reductions of 14.9% over 68 weeks, while SURMOUNT-1 showed tirzepatide achieving 15-20.9% reductions depending on dose [5]. These comparable efficacy profiles support successful transitions between the two medications.

Most patients switching from Mounjaro to Wegovy report sustained appetite suppression and continued weight loss or maintenance during the first 3-6 months post-transition. Some individuals experience slightly different side effect profiles, with semaglutide potentially causing less injection site reactions but similar rates of nausea and gastrointestinal effects during dose escalation. Individual responses vary, making close monitoring during the switch from Mounjaro to Wegovy essential for optimising outcomes.

Managing Side Effects During the Switch From Mounjaro To Wegovy

The most commonly reported side effects when switching from Mounjaro to Wegovy include transient nausea, altered bowel habits, and reduced appetite intensity. These effects typically mirror the initial Mounjaro experience but may feel more pronounced if the starting Wegovy dose is too high relative to your previous tirzepatide dose. Starting at 0.25mg weekly and following the prescribed titration schedule minimises these transition-related effects [6].

Practical strategies for managing side effects include eating smaller, more frequent meals, avoiding high-fat foods that delay gastric emptying further, and maintaining adequate hydration. If you experience persistent nausea or vomiting during your switch from Mounjaro to Wegovy, contact your prescriber before your next scheduled dose increase. At Cured Pharmacy, our clinical team remains available to address concerns and coordinate with prescribers to adjust titration schedules when medically appropriate.

Supply and Availability: Switch From Mounjaro To Wegovy Considerations

UK supply dynamics significantly influence decisions to switch from Mounjaro to Wegovy. Wegovy has demonstrated more consistent availability through UK wholesalers since mid-2023, whereas Mounjaro has experienced periodic supply constraints affecting certain dose strengths. For patients requiring uninterrupted treatment, Wegovy's supply stability offers practical advantages beyond cost considerations.

Cured Pharmacy maintains relationships with multiple UK-licensed wholesalers to ensure reliable access to both medications. Our transparent stock status system allows patients to verify Wegovy availability before initiating the switch from Mounjaro to Wegovy, preventing treatment gaps that could compromise weight management progress. All medications dispensed are genuine UK-licensed products, never grey market imports, ensuring consistent quality and regulatory compliance.

The regulatory landscape also favours Wegovy for certain patient groups. NHS England's recent commissioning decisions have prioritised semaglutide for specialist weight management services, potentially facilitating future NHS access for patients currently purchasing privately. While this doesn't affect immediate private prescription availability, it signals long-term sustainability that may influence your decision to switch from Mounjaro to Wegovy [7].

How to Initiate Your Switch From Mounjaro To Wegovy at Cured Pharmacy

Beginning your switch from Mounjaro to Wegovy through Cured Pharmacy involves a streamlined three-step process designed for clinical safety and convenience. First, complete our online clinical assessment, which takes under three minutes and captures your current Mounjaro dose, treatment duration, weight loss progress, and any side effects experienced. This information allows our UK-registered prescribers to determine the appropriate starting dose of Wegovy for your individual circumstances.

Second, a UK prescriber reviews your assessment within 24 hours, considering your Mounjaro treatment history and current health status. If clinically appropriate, they'll issue a prescription for Wegovy with personalised titration guidance. Our prescribers may recommend starting at a specific dose based on your current tirzepatide level, or following the standard escalation schedule if you're transitioning from lower Mounjaro doses.

Third, once approved, your Wegovy prescription is dispensed by our GPhC-registered pharmacy (9012511) and dispatched via next-day delivery in 100% discreet packaging. We include comprehensive administration instructions and transition guidance specific to patients switching from Mounjaro to Wegovy. Ongoing prescriptions are managed through simple monthly renewals, with clinical check-ins ensuring your transition remains on track and effective.

Documentation Required for Switching From Mounjaro To Wegovy

To facilitate a safe switch from Mounjaro to Wegovy, our clinical assessment requests details of your current treatment regimen, including your present Mounjaro dose, duration of use, total weight lost, and baseline BMI when you started tirzepatide. This historical context helps prescribers make informed decisions about appropriate Wegovy starting doses and titration speeds. If you have documentation from your previous prescriber regarding your Mounjaro treatment, this can be helpful but isn't mandatory.

Patients with additional health conditions, particularly type 2 diabetes, should disclose current medications and recent HbA1c levels if available. While both Mounjaro and Wegovy affect glycaemic control, the transition between medications may require temporary diabetes medication adjustments. Our prescribers coordinate with your existing healthcare providers when necessary to ensure comprehensive care during your switch from Mounjaro to Wegovy, maintaining therapeutic continuity across all aspects of your health management.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2023). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 29(10), 2473-2488. [accessed 15 August 2026]
6. Wadden, T. A., Bailey, T. S., Billings, L. K., et al. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA, 325(14), 1403-1413. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.